• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 57Pooled relative risks and other adverse event rates—epoetin or darbepoetin versus control

OutcomeTrialsESA NControl NRR (95% CI)I2Incidence ESA (95% CI)Incidence Control (95% CI)
Hypertension16a2,3022,0161.48 (1.07 to 2.06)0%3.8% (2.7 to 5.0)2.1% (1.1 to 3.4)
Thrombocytopenia and/or Hemorrhage122,0181,6961.17 (1.01 to 1.36)0%12.2% (5.5 to 20.9)9.9% (3.9 to 17.8)
Rash5b7397282.00 (0.98 to 4.07)0%2.3% (0.2 to 5.6)1.0% (0.0 to 3.3)
Seizures58547330.93 (0.43 to 2.04)0%2.1% (1.2 to 3.1)1.8% (0.6 to 3.7)

CI = confidence interval; ESA = erythropoiesis-stimulating agent; RR = relative risk

a

Excluding one trial with no events106 and one outlier.118

b

Result excludes one trial with no events.103

Excluding one trial with no events106 and one outlier.118

Result excludes one trial with no events.103

From: Results

Cover of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update [Internet].
Comparative Effectiveness Reviews, No. 113.
Grant MD, Piper M, Bohlius J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.